Skip to content

US · EBS · BIOTECHNOLOGY

Emergent BioSolutions Inc. (EBS) intrinsic value and stock valuation

$5.05as of 2026-11-21 · Mkt cap 389.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Emergent BioSolutions Inc. DCF and intrinsic value

InvestorsCraft values EBS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EBS’s statements →

Emergent BioSolutions Inc. Graham Number

Graham Number: $14.70d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Gaithersburg, MD 20879 emergentbiosolutions.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$742.9M-14% 5y CAGRd
20112025
Net income
$52.6M-29.7% 5y CAGRd
20112025
Free cash flow
$156.8M-16.9% 5y CAGRd
20112025
Total equity
$522.6M-18.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$742.9M$1.04B$1.05B$1.12B$1.77B
Operating income$110.2M-$-108.7M-$-726.4M-$-170M$341.4M
Net income$52.6M-$-190.6M-$-760.5M-$-211.6M$219.5M
EPSd$927.7K-$-3.6M-$-14.85M-$-4.22M$4.06M
Operating cash flow$170.6M$58.7M-$-206.3M-$-34.1M$321.1M
Capital expenditure-$-13.8M-$-22.9M-$-51.6M-$-115.8M-$-225M
Free cash flow$156.8M$35.8M-$-257.9M-$-149.9M$96.1M
Total assets$1.32B$1.39B$1.82B$3.17B$2.96B
Total debt$572.1M$676.1M$860.2M$1.43B$871M
Net debt$366.7M$576.6M$748.5M$783.8M$294.7M
Total equity$522.6M$482.8M$649.3M$1.39B$1.61B
Cash and short-term investments$205.4M$99.5M$111.7M$642.6M$576.3M
Income statement
20252024202320222021
Revenue$742.9M$1.04B$1.05B$1.12B$1.77B
Cost of revenue$392.3M$668.2M$689.3M$644.5M$980.4M
Gross profit$350.6M$375.4M$360M$473M$793.2M
Research and development expenses$53.8M$70.7M$111.4M$188.3M$235.2M
Selling, general and administrative expenses$186.6M$298.7M$356.7M$339.5M$348.7M
Other expenses$0.00$114.7M$618.3M$115.2M-$-132.1M
Operating expenses$240.4M$484.1M$1.09B$643M$451.8M
Cost and expenses$632.7M$1.15B$1.78B$1.29B$1.43B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$59.3M$71M$87.9M$37.3M$34.5M
Depreciation and amortization$98.3M$105.6M$121.1M$125M$118.2M
Ebitda$240.4M$53.4M-$-47M$15.7M$504.2M
Operating income$110.2M-$-108.7M-$-726.4M-$-170M$341.4M
Total other income/expenses, net-$-27.4M-$-34.2M-$-4.8M-$-49M-$-38.2M
Income before tax$82.8M-$-142.9M-$-731.2M-$-219M$303.2M
Income tax expense$30.2M$47.7M$29.3M-$-7.4M$83.7M
Net income$52.6M-$-190.6M-$-760.5M-$-211.6M$219.5M
Weighted average shares outstanding$53.5M$53M$51.2M$50.1M$53.5M
Weighted average diluted shares outstanding$56.7M$53M$51.2M$50.1M$54.1M
Balance sheet
20252024202320222021
Cash and short-term investments$205.4M$99.5M$111.7M$642.6M$576.3M
Net receivables$84.2M$154.5M$191M$159.2M$278.9M
Inventory$343.4M$311.7M$328.9M$350.7M$344.5M
Total current assets$662.5M$598.7M$679.5M$1.21B$1.27B
Property, plant and equipment, net$205.4M$270.6M$399M$837M$828.4M
Goodwill and intangible assets$436.5M$501.5M$566.6M$947M$829.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$656.1M$791M$1.14B$1.96B$1.69B
Total assets$1.32B$1.39B$1.82B$3.17B$2.96B
Accounts payable$55.6M$60.9M$112.2M$103.5M$128.9M
Short-term debt$0.00$2.7M$413.7M$963.1M$37.4M
Deferred revenue$0.00$0.00$0.00$26.4M$11.7M
Total current liabilities$132.2M$162.4M$651.3M$1.23B$374M
Long-term debt$572.1M$673.4M$446.5M$463.3M$833.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$4.7M
Total non-current liabilities$663.8M$744.5M$522.6M$549.7M$972.2M
Capital lease obligations$0.00$9.7M$0.00$14.8M$24.2M
Total liabilities$796M$906.9M$1.17B$1.78B$1.35B
Common stock$100K$100K$100K$100K$100K
Retained earnings-$-159.8M-$-212.4M-$-21.8M$738.7M$950.3M
Accumulated other comprehensive income (loss)-$-7.5M-$-5.2M-$-5.7M$3.1M-$-16.1M
Total equity$522.6M$482.8M$649.3M$1.39B$1.61B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$572.1M$676.1M$860.2M$1.43B$871M
Net debt$366.7M$576.6M$748.5M$783.8M$294.7M
Cash flow statement
20252024202320222021
Net income$52.6M-$-190.6M-$-760.5M-$-211.6M$230.9M
Depreciation and amortization$95.8M$108.8M$125.1M$143.3M$123.8M
Stock-based compensation$16.2M$18M$23.1M$45.1M$42.4M
Change in working capital-$-22.4M$88.7M-$-70.3M-$-2.1M-$-156.4M
Accounts receivable$25.5M-$-24.4M-$-21.6M$118.1M-$-48.2M
Inventory-$-30.3M-$-24.5M$600K-$-57.1M-$-44M
Accounts payable-$-8.4M-$-33M$10.6M-$-14M-$-2.5M
Net cash provided by operating activities$170.6M$58.7M-$-206.3M-$-34.1M$321.1M
Investments in property, plant and equipment-$-13.8M-$-22.9M-$-51.6M-$-115.8M-$-225M
Acquisitions, net$0.00$0.00$270.2M$0.00$0.00
Net cash used for investing activities$69.4M$125.2M$212.3M-$-381.3M-$-225M
Common stock issued$2.2M$9.3M$8.4M$0.00$0.00
Common stock repurchased-$-24.9M$0.00$0.00-$-82.1M-$-106M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-136.6M-$-190M-$-535.7M$481.2M-$-141M
Net change in cash$103.5M-$-6.1M-$-530.9M$66.3M-$-45.2M
Cash at end of period$209.1M$105.6M$111.7M$642.6M$576.3M
Operating cash flow$170.6M$58.7M-$-206.3M-$-34.1M$321.1M
Capital expenditure-$-13.8M-$-22.9M-$-51.6M-$-115.8M-$-225M
Free cash flow$156.8M$35.8M-$-257.9M-$-149.9M$96.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Emergent BioSolutions Inc.

        Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

        CEO
        Joseph C. Papa Jr.
        Employees
        900
        Beta
        2.34

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Emergent BioSolutions Inc. (EBS)?

        InvestorsCraft does not currently publish an intrinsic value for EBS. How the IC value is calculated.

        Is EBS undervalued?

        InvestorsCraft does not publish an undervaluation signal for EBS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.